Fig. 3: IDO-Gal3 treatment decreased psoriasis-related immune cell populations and activation in psoriatic skin. | npj Biomedical Innovations

Fig. 3: IDO-Gal3 treatment decreased psoriasis-related immune cell populations and activation in psoriatic skin.

From: Indoleamine 2,3-dioxygenase-galectin-3 fusion protein remodels inflammatory and fibrotic programs, ameliorating imiquimod-induced psoriasis

Fig. 3

a Percent CD11b+ GR-1+ cells in the dermis and epidermis, with representative histograms. Fewer neutrophils are in the epidermis following IDO-Gal3 treatment as compared to PBS control. b Percent CD11b- TCRαβ + CD44+ cells in the dermis and epidermis, with representative histograms. c Percent CD11b- TCRαβ + CD4 + CD44+ cells in the dermis and epidermis, with representative histograms. Fewer activated αβ and CD4+ helper T cells are in the dermis following IDO-Gal3 treatment as compared to PBS. d Percent CD11b- TCRγδ + CD44+ cells in the dermis and epidermis, with representative histograms. e Percent CD11b- TCRγδ + CCR6+ cells in the dermis and epidermis, with representative histograms. f Percent CD11b- TCRγδ + RORγt+ cells in the dermis and epidermis, with representative histograms. Fewer activated TCRγδ+ cells are in the dermis following IDO-Gal3 treatment as compared to PBS. All populations were compared using an unpaired t-test; *P < 0.05; **P < 0.01; ***P < 0.001. No comparison indicates no significance.

Back to article page